VEGF-D/VEGFR2/3-mediated regulation of dendrites

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9415090
APP PUB NO 20140093520A1
SERIAL NO

14122116

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and/or disease-related cognitive dysfunctions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
FUNDAMENTAL PHARMA GMBHJOHANN-FISCHER-STR 2 HEIDELBERG 69121

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bading, Hilmar Heidelberg, DE 4 1
Klein, Christian Heidelberg, DE 571 9941
Mauceri, Daniela Heidelberg, DE 2 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 16, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00